Proportion of participants with BCVA of 20/100 or better at 4 to 8 weeks Assessed using a logMAR chart · participants of any age with confirmed cases of bacterial keratitis
1 finding from 1 review
no estimate extracted
12 participants
Very low
Mean change from baseline in BCVA at 4 to 8 weeks Assessed using a logMAR chart · participants of any age with confirmed cases of bacterial keratitis
1 finding from 1 review
no estimate extracted
0 participants
GRADE not reported
Proportion of participants with a reduction in corneal infiltrate at 4 to 8 weeks Assessed by outcome assessors · participants of any age with confirmed cases of bacterial keratitis
1 finding from 1 review
no estimate extracted
0 participants
GRADE not reported
Proportion of participants with reduction in intraocular inflammation at 4 to 8 weeks Assessed by corneal keratic precipitates, anterior chamber cellular reaction, or other appropriate measure · participants of any age with confirmed cases of bacterial keratitis
1 finding from 1 review
no estimate extracted
0 participants
GRADE not reported
Proportion of participants with treatment failure at 4 to 8 weeks Assessed by outcome assessors · participants of any age with confirmed cases of bacterial keratitis
1 finding from 1 review
Proportion of participants with adverse events at 4 to 8 weeks Assessed by outcome assessors · participants of any age with confirmed cases of bacterial keratitis
1 finding from 1 review
Overall survival · women with early breast cancer
Taxane‐containing chemotherapy leads to lower overall survival compared with any chemotherapy without taxane (high certainty).
1 finding from 1 review
Disease‐free progression · women with early breast cancer
Taxane‐containing chemotherapy leads to lower disease‐free progression compared with any chemotherapy without taxane (high certainty).
1 finding from 1 review
Quality of life · women with early breast cancer
1 finding from 1 review
Febrile neutropenia · women with early breast cancer
Taxane‐containing chemotherapy showed no clear difference in febrile neutropenia compared with any chemotherapy without taxane (moderate certainty).
1 finding from 1 review
Neuropathy (including grade 3/4 sensory or motor neuropathy, or both) · women with early breast cancer
Taxane‐containing chemotherapy probably leads to higher neuropathy (including grade 3/4 sensory or motor neuropathy, or both) compared with any chemotherapy without taxane (moderate certainty).
1 finding from 1 review
Cardiotoxicity (including grade 3/4 and congestive cardiac failure) · women with early breast cancer
Taxane‐containing chemotherapy showed no clear difference in cardiotoxicity (including grade 3/4 and congestive cardiac failure) compared with any chemotherapy without taxane (moderate certainty).
1 finding from 1 review
BADL (primary outcome) · adults with cognitive impairment after stroke
1 finding from 1 review
no estimate extracted
1 participants
GRADE not reported
5a. Visual attention overall (postintervention) · adults with cognitive impairment after stroke
2 findings from 1 review
5c. Sustained visual attention (postintervention) · adults with cognitive impairment after stroke
1 finding from 1 review
Memory (specific cognitive function) · adults with cognitive impairment after stroke
1 finding from 1 review
no estimate extracted
6 participants
GRADE not reported
Cognitive subdomain: working memory measured at the end of · adults with cognitive impairment after stroke
1 finding from 1 review
6b. Immediate verbal memory span (postintervention) · adults with cognitive impairment after stroke
1 finding from 1 review
6c. Immediate spatial memory span (postintervention) · adults with cognitive impairment after stroke
1 finding from 1 review
Executive function (specific cognitive function) · adults with cognitive impairment after stroke
1 finding from 1 review
no estimate extracted
7 participants
GRADE not reported